Editorial Material
Hematology
Gary Schiller
Summary: The study introduces a convenient clinical prognostic tool based on cytogenetic and molecular profiling to identify which group of older and fit AML patients may benefit from intensive induction and consolidation chemotherapy.
Article
Oncology
Claudia A. M. Stege, Kazem Nasserinejad, Ellen Van der Spek, Yavuz M. Bilgin, Alain Kentos, Maaike Sohne, Roel J. W. van Kampen, Inge Ludwig, Noortje Thielen, Nazik Durdu-Rayman, Nicole C. H. P. de Graauw, Niels W. C. J. van de Donk, Esther G. M. de Waal, Marie-Christiane Vekemans, Gert Jan Timmers, Marjolein van Der Klift, Savita Soechit, Paul A. F. Geerts, Matthijs H. Silbermann, Margriet Oosterveld, Inger S. Nijhof, Pieter Sonneveld, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Summary: The study conducted Ixa-Dara-dex treatment for frail multiple myeloma patients, showing good induction efficacy but high treatment discontinuation rate due to toxicity and early mortality, negatively impacting PFS and OS. Outcome was heterogeneous across different frail subpopulations.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Hematology
Anita W. Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J. Biemond, Arjen A. van de Loosdrecht, Lotte E. van der Wagen, Mar Bellido, Michel van Gelder, Walter J. F. M. van der Velden, Dominik Selleslag, Danielle Van Lammeren-Venema, Constantijn J. M. Halkes, Rob Fijnheer, Violaine Havelange, Geerte L. van Sluis, Marie-Cecile Legdeur, Dries Deeren, Alain Gadisseur, Harm A. M. Sinnige, Dimitri A. Breems, Aurelie Jaspers, Ollivier Legrand, Wim E. Terpstra, Rinske S. Boersma, Dominiek Mazure, Agnes Triffet, Lidwine W. Tick, Karolien Beel, Johan A. Maertens, H. Berna Beverloo, Marleen Bakkus, Christa H. E. Homburg, Valerie de Haas, Vincent H. J. van der Velden, Jan J. Cornelissen
Summary: Clofarabine (CLO) has efficacy in relapsed/refractory acute lymphoblastic leukemia (ALL). However, adding CLO to induction and consolidation did not improve outcome in adults with newly diagnosed ALL. Although some patients achieved minimal residual disease (MRD) negativity, CLO-treated patients experienced more serious adverse events and infections.
Article
Hematology
Thierry Facon, Christopher P. Venner, Nizar J. Bahlis, Fritz Offner, Darrell J. White, Lionel Karlin, Lotfi Benboubker, Sophie Rigaudeau, Philippe Rodon, Eric Voog, Sung-Soo Yoon, Kenshi Suzuki, Hirohiko Shibayama, Xiaoquan Zhang, Philip Twumasi-Ankrah, Godwin Yung, Robert M. Rifkin, Philippe Moreau, Sagar Lonial, Shaji K. Kumar, Paul G. Richardson, S. Vincent Rajkumar
Summary: Continuous treatment with lenalidomide-dexamethasone (Rd) plus ixazomib showed a progression-free survival benefit compared to placebo in transplant-ineligible newly diagnosed multiple myeloma patients. Addition of ixazomib to Rd led to higher rates of complete and very good partial response, especially in high-risk cytogenetics subgroup. The combination therapy was generally well-tolerated with manageable toxicities and no new safety signals observed.
Article
Oncology
Jason Westin, R. Eric Davis, Lei Feng, Fredrick Hagemeister, Raphael Steiner, Hun Ju Lee, Luis Fayad, Loretta Nastoupil, Sairah Ahmed, Alma Rodriguez, Michelle Fanale, Felipe Samaniego, Swaminathan P. Iyer, Ranjit Nair, Yasuhiro Oki, Nathan Fowler, Michael Wang, Man Chun John Ma, Francisco Vega, Timothy McDonnell, Chelsea Pinnix, Donna Griffith, Yang Lu, Sanjit Tewari, Ryan Sun, David W. Scott, Christopher R. Flowers, Sattva Neelapu, Michael R. Green
Summary: This study introduces a new treatment strategy (RLI) for newly diagnosed DLBCL patients, which combines targeted therapy with drugs before chemotherapy. The results showed high treatment response rates and durable responses in DLBCL patients treated with RLI. This establishes the potential for developing biologically driven and noncytotoxic first-line therapies for DLBCL.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Hematology
Peter A. Forsberg, Adriana C. Rossi, Angelique Boyer, Roger N. Pearse, Karen A. Pekle, David Jayabalan, Stephanie Lakritz, Kari Flicker, Drew Ribadeneyra, Brielle Liotta, Scott Ely, Leora Boussi, John N. Allan, Morton Coleman, Ruben Niesvizky, Tomer M. Mark
Summary: The study evaluated a new treatment regimen for multiple myeloma called Car-BiRd and found that it can achieve similar outcomes with reduced toxicities compared to standard treatment regimens. The results showed a high overall response rate in newly diagnosed MM patients and suggest that the sequential Car-BiRd regimen is an effective and safe approach for upfront treatment.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Article
Oncology
Zhongjun Huo, Fang Chen, Ping Liu, Zimian Luo
Summary: This study compares the response and safety of Ixazomib/Lenalidomide/Dexamethasone (IRd) and Bortezomib/Lenalidomide/Dexamethasone (VRd) treatments in newly diagnosed multiple myeloma. The results show that IRd has similar efficacy to VRd, but with better safety and may be more suitable for patients with poor baseline conditions.
Article
Oncology
Grzegorz S. Nowakowski, Fangxin Hong, David W. Scott, William R. Macon, Rebecca L. King, Thomas M. Habermann, Nina Wagner-Johnston, Carla Casulo, James L. Wade, Gauri G. Nagargoje, C. M. Reynolds, Jonathon B. Cohen, Nadia Khan, Jennifer E. Amengual, Kristy L. Richards, R. F. Little, John P. Leonard, Jonathan W. Friedberg, Lale Kostakoglu, Brad S. Kahl, Thomas E. Witzig
Summary: The addition of lenalidomide to R-CHOP (R2CHOP) in newly diagnosed DLBCL, particularly in the ABC-DLBCL subtype, showed improved outcomes including better progression-free survival and overall survival rates. This study suggests that R2CHOP may be an effective treatment option for patients with DLBCL, especially those with the ABC-DLBCL subtype.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Luciano J. Costa, Saurabh Chhabra, Eva Medvedova, Bhagirathbhai R. Dholaria, Timothy M. Schmidt, Kelly N. Godby, Rebecca Silbermann, Binod Dhaka, Susan Bal, Smith Gid, Anita D'Souza, Aric Hall, Pamela Hardwick, James Omel, Robert F. Cornell, Parameswaran Had, Natalie S. Callander
Summary: Dara-KRd, AHCT, and MRD response-adapted consolidation lead to a high rate of MRD negativity in NDMM patients. This strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance for patients with 0 or 1 HRCA.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Carlyn Rose Tan, Andriy Derkach, David Nemirovsky, Amanda Ciardiello, Benjamin Diamond, Malin Hultcrantz, Hani Hassoun, Sham Mailankody, Urvi Shah, Kylee Maclachlan, Dhwani Patel, Oscar B. B. Lahoud, Heather J. J. Landau, David J. J. Chung, Gunjan L. L. Shah, Michael Scordo, Sergio A. A. Giralt, Alexander Lesokhin, Saad Z. Z. Usmani, Ola Landgren, Neha Korde
Summary: This retrospective study compared the efficacy and safety of VRd and KRd as induction regimens. The results showed that KRd was associated with improved progression-free survival (PFS) and event-free survival (EFS) compared to VRd, with a more significant improvement observed in high-risk patients.
BLOOD CANCER JOURNAL
(2023)
Article
Hematology
Hua-Jay J. Cherng, Stefan K. Alig, Yasuhiro Oki, Loretta J. Nastoupil, Luis Fayad, Sattva S. Neelapu, Francesco Turturro, Fredrick Hagemeister, Alexander F. M. Craig, Charles W. Macaulay, Maria Alma Rodriguez, Hun Ju Lee, Timothy J. McDonnell, Christopher R. Flowers, Francisco Vega, Michael R. Green, Lei Feng, David M. Kurtz, Ash A. Alizadeh, R. Eric Davis, Jason R. Westin
Summary: LO-CHOP treatment shows high efficacy and tolerability in newly diagnosed DLBCL, leading to a high rate of overall and complete response. It is a potentially effective and well-tolerated treatment option.
Article
Hematology
Florian Langer, Hanna Quick, Antonia Beitzen-Heineke, Snjezana Janjetovic, Jonathan Maeder, Carina Lehr, Carsten Bokemeyer, Piotr Kuta, Thomas Renne, Walter Fiedler, Lennart Beckmann, Felix Klingler, Christina C. Rolling
Summary: Patients with acute myeloid leukemia (AML) have an increased risk of thrombohemorrhagic complications. The heme enzyme myeloperoxidase (MPO) negatively regulates tissue factor (TF) procoagulant activity (PCA) on myelomonocytic cells. Our study indicates that catalytically active MPO released by circulating myeloblasts regulates TF-dependent coagulation in patients with newly diagnosed AML in a CD18-dependent manner.
THROMBOSIS RESEARCH
(2023)
Review
Multidisciplinary Sciences
Qiukui Hao, Farid Foroutan, Mi Ah Han, Tahira Devji, Fernando Kenji Nampo, Sudipto Mukherjee, Shabbir M. H. Alibhar, Ashley Roske, Mikkael A. Sekeres, Gordon H. Guyatt, Romina Brignardello-Petersen
Summary: This systematic review found that age, comorbidities, and performance status are associated with long-term mortality in older patients with acute myeloid leukemia (AML) undergoing antileukemic treatment. However, the studies on short-term mortality and quality of life provided inconsistent results.
Article
Oncology
Thierry Facon, Gordon Cook, Saad Z. Usmani, Cyrille Hulin, Shaji Kumar, Torben Plesner, Cyrille Touzeau, Nizar J. Bahlis, Supratik Basu, Hareth Nahi, Hartmut Goldschmidt, Hang Quach, Mohamad Mohty, Christopher P. Venner, Katja Weisel, Noopur Raje, Benjamin Hebraud, Karim Belhadj-Merzoug, Lotfi Benboubker, Olivier Decaux, Salomon Manier, Denis Caillot, Jon Ukropec, Huiling Pei, Rian Van Rampelbergh, Clarissa M. Uhlar, Rachel Kobos, Sonja Zweegman
Summary: In patients with transplant-ineligible newly diagnosed multiple myeloma, the combination of daratumumab plus lenalidomide/dexamethasone improved progression-free survival compared to lenalidomide/dexamethasone alone. This benefit was observed regardless of patients' frailty status. Daratumumab showed improved response rates and minimal residual disease negativity across subgroups.
Article
Oncology
Thierry Facon, Shaji K. Kumar, Torben Plesner, Robert Z. Orlowski, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Joseph R. Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa M. Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Z. Usmani
Summary: In patients with newly diagnosed multiple myeloma who are ineligible for stem-cell transplantation, daratumumab plus lenalidomide and dexamethasone significantly improved overall survival and progression-free survival with no new safety concerns.
Article
Oncology
Kim Klein, H. Berna Beverloo, Martin Zimmermann, Susana C. Raimondi, Christine von Neuhoff, Valerie Haas, Romy van Weelderen, Jacqueline Cloos, Jonas Abrahamsson, Yves Bertrand, Michael Dworzak, Alcira Fynn, Brenda Gibson, Shau-Yin Ha, Christine J. Harrison, Henrik Hasle, Sarah Elitzur, Guy Leverger, Alexei Maschan, Bassem Razzouk, Dirk Reinhardt, Carmelo Rizzari, Pter Smisek, Ursula Creutzig, Gertjan J. L. Kaspers
Summary: Cytogenetic profiles and karyotypic changes at relapse play a significant role in predicting survival outcomes for children with relapsed AML, with certain abnormalities associated with better or worse prognosis. Early treatment response, time to relapse, and cytogenetic profile at relapse are important prognostic factors, outweighing karyotypic instability per se.
PEDIATRIC BLOOD & CANCER
(2022)
Article
Medical Laboratory Technology
Costa Bachas, Carolien Duetz, Margot F. van Spronsen, Jan Verhoeff, Juan J. Garcia Vallejo, Joop H. Jansen, Jacqueline Cloos, Theresia M. Westers, Arjan A. van de Loosdrecht
Summary: Through mass cytometry and computational data analysis, we were able to characterize HSPC subsets in MDS and identify leukemia stem cell populations based on their immunophenotype. Stem cells in MDS that display leukemia-associated features may predict the risk of developing AML.
CYTOMETRY PART B-CLINICAL CYTOMETRY
(2023)
Correction
Medicine, Research & Experimental
Aslaug Helland, Hege G. Russnes, Gro Live Fagereng, Khalid Al-Shibli, Yvonne Andersson, Thomas Berg, Line Bjorge, Egil Blix, Bodil Bjerkehagen, Sigmund Brabrand, Marte Gronlie Cameron, Astrid Dalhaug, Dalia Dietzel, Tom Donnem, Espen Enerly, Asmund Flobak, Sverre Fluge, Bjornar Gilje, Bjorn Tore Gjertsen, Bjorn Henning Gronberg, Kari Gronas, Tormod Guren, Hanne Hamre, Ase Haug, Daniel Heinrich, Geir Olav Hjortland, Eivind Hovig, Randi Hovland, Ann-Charlotte Iversen, Emiel Janssen, Jon Amund Kyte, Hedda von der Lippe Gythfeldt, Ragnhild Lothe, Jo-Asmund Lund, Leonardo Meza-Zepeda, Monica Cheng Munthe-Kaas, Olav Toai Duc Nguyen, Pitt Niehusmann, Hilde Nilsen, Katarina Puco, Anne Hansen Ree, Tonje Boyum Riste, Karin Semb, Eli Sihn Samdal Steinskog, Andreas Stensvold, Pal Suhrke, Oyvind Tennoe, Geir E. Tjonnfjord, Liv Jorunn Vassbotn, Eline Aas, Kristine Aasebo, Kjetil Tasken, Sigbjorn Smeland
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Immunology
Anna Vyborova, Anke Janssen, Lucrezia Gatti, Froso Karaiskaki, Austin Yonika, Sanne van Dooremalen, Jasper Sanders, Dennis X. Beringer, Trudy Straetemans, Zsolt Sebestyen, Juergen Kuball
Summary: This study highlights the role of CDR3δ in modulating T-cell responses and identifies a CDR3δ bias in the NKR landscape of gamma 9 delta 2T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Benedicte Sjo Tislevoll, Monica Hellesoy, Oda Helen Eck Fagerholt, Stein-Erik Gullaksen, Aashish Srivastava, Even Birkeland, Dimitrios Kleftogiannis, Pilar Ayuda-Duran, Laure Piechaczyk, Dagim Shiferaw Tadele, Jorn Skavland, Baliakas Panagiotis, Randi Hovland, Vibeke Andresen, Ole Morten Seternes, Tor Henrik Anderson Tvedt, Nima Aghaeepour, Sonia Gavasso, Kimmo Porkka, Inge Jonassen, Yngvar Floisand, Jorrit Enserink, Nello Blaser, Bjorn Tore Gjertsen
Summary: In this study, the initial signaling response to standard induction chemotherapy in 32 acute myeloid leukemia (AML) patients was investigated using 36-dimensional mass cytometry. The reduction of extracellular-signal-regulated kinase (ERK) 1/2 and p38 mitogen-activated protein kinase (MAPK) phosphorylation in the myeloid cell compartment 24 h post-chemotherapy was found to be a significant predictor of patient 5-year overall survival in this cohort. This study demonstrates the value of mass cytometry in early response evaluation in AML and highlights the potential of functional signaling analyses in precision oncology diagnostics.
NATURE COMMUNICATIONS
(2023)
Article
Immunology
Eline van Diest, Mara J. T. Nicolasen, Lovro Kramer, Jiali Zheng, Patricia Hernandez-Lopez, Dennis X. Beringer, Jurgen Kuball
Summary: In this study, we developed a novel T cell engager concept called GAB by utilizing γδTCR as a tumor targeting domain. The γδ ECTO-alpha CD3-dimer design was found to be superior in function compared to monomers and does not induce T cell activation without simultaneous tumor engagement.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Biophysics
Klaartje Nijssen, Kasper Westinga, Anniek Stuut, Anke Janssen, Anna van Rhenen, Lotte van der Wagen, Laura G. M. Daenen, Rimke Oostvogels, Moniek A. de Witte, Juergen Kuball
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
Laura G. M. Daenen, Jan-Tom van der Bruggen, Roos J. Leguit, Lotte E. van der Wagen, Anna van Rhenen, Herman F. Wunderink, Moniek A. de Witte, Anke H. W. Bruns, Jurgen Kuball
BONE MARROW TRANSPLANTATION
(2023)
Letter
Biophysics
M. A. de Witte, J. E. Mooyaart, J. D. Hoogenboom, C. Chabannon, F. Malard, A. Ruggeri, J. Kuball
BONE MARROW TRANSPLANTATION
(2023)
Article
Oncology
Thomas Kimman, Anne Slomp, Anne Martens, Sarah Grabherr, Shuang Li, Eline van Diest, Jan Meeldijk, Jurgen Kuball, Monique C. Minnema, Eric Eldering, Niels Bovenschen, Zsolt Sebestyen, Victor Peperzak
Summary: Gene engineered CAR T cells have shown promising initial clinical responses in cancer patients; however, resistance mechanisms in cancer cells can limit the effectiveness of CAR T cell-mediated killing. Serpin B9 expression in cancer cells can lead to resistance towards CAR T cells, and inhibiting or bypassing serpin B9 may improve CAR T cell responses.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Hematology
Peter Hokland, Isolda I. Fernandez, Sylvie D. Freeman, Bjorn T. Gjertsen, Jie Jin, Vidh Murthy, Masamitsu Yanada, Arnold Ganser
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Editorial Material
Hematology
Bjorn Tore Gjertsen
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Yngvar Floisand, Mats Remberger, Iris Bigalke, Dag Josefsen, Helen Valerhaugen, Else Marit Inderberg, Richard W. Olaussen, Bjorn Tore Gjertsen, Rene Goedkoop, Christiane Geiger, Petra U. Prinz, Frauke M. Schnorfeil, Kai Pinkernell, Dolores J. Schendel, Gunnar Kvalheim
Summary: For relapsing AML patients not suitable for allo-HSCT, oral azacytidine can be used as maintenance treatment in first remission, but it has substantial side effects and less toxic alternatives should be explored. In this study, autologous RNA-loaded mature dendritic cell vaccine FDC101 was used as maintenance therapy in CR1 AML patients, and the results showed good tolerability and high long-term survival.
Article
Oncology
Brunangelo Falini, Bjorn T. Gjertsen, Vibeke Andresen
Meeting Abstract
Biophysics
D. P. Mclornan, I. Martin, T. Sirait, T. Schroeder, I. W. Blau, J. Kuball, J. Byrne, M. Colin, M. Stradler, D. Desmier, U. Salmenniemi, P. Jindra, N. Mikhailova, S. Lenhoff, J. Rifon, M. Robin, M. Rovira, J. H. Veelken, A. Sadowska-Klasa, M. Zecca, L. Gras, P. J. Hayden, T. Czerw, J. C. Hernandez-Boluda, I. Yakoub-Agha
BONE MARROW TRANSPLANTATION
(2022)